Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to $98.9 million.

  • Monte Rosa Therapeutics' Cash from Financing Activities rose 2220.00% to $348,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year decrease of 98.92%. This contributed to the annual value of $98.9 million for FY2024, which is 259.71% up from last year.
  • Monte Rosa Therapeutics' Cash from Financing Activities amounted to $98.9 million in FY2024, which was up 259.71% from $27.5 million recorded in FY2023.
  • Monte Rosa Therapeutics' 5-year Cash from Financing Activities high stood at $377.6 million for FY2021, and its period low was $20.5 million during FY2022.
  • For the 3-year period, Monte Rosa Therapeutics' Cash from Financing Activities averaged around $49.0 million, with its median value being $27.5 million (2023).
  • As far as peak fluctuations go, Monte Rosa Therapeutics' Cash from Financing Activities skyrocketed by 528.64% in 2021, and later tumbled by 94.58% in 2022.
  • Monte Rosa Therapeutics' Cash from Financing Activities (Yearly) stood at $60.1 million in 2020, then soared by 528.64% to $377.6 million in 2021, then plummeted by 94.58% to $20.5 million in 2022, then skyrocketed by 34.33% to $27.5 million in 2023, then skyrocketed by 259.71% to $98.9 million in 2024.